Navigation Links
BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
Date:1/8/2009

nd other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current phar
'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
2. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
3. BioCryst to Present at UBS 2007 Global Life Sciences Conference
4. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
5. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
6. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. BioCryst to Present at UBS 2008 Global Life Sciences Conference
11. BioCryst to Present at the JMP Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and ... 2014 at Double Tree by Hilton Beijing, China is ... Analytical & Bioanalytical research methods only to facilitate improved ... occasion, Dr. Srinubabu Gedela, MD of OMICS Group Inc ... remarkable one in bringing a unique and international mix ...
(Date:7/10/2014)... July 10, 2014  Kainos Capital, a firm specializing ... announced that it has acquired the Slim-Fast brand from ... business. Terms of the transaction were not disclosed. ... replacement business that markets ready-to-drink shakes, powders, bars and ... and in the United Kingdom ...
(Date:7/10/2014)... in the fight against terrorism with the creation of ... with the use of light and special glass fibres. ... B: Chemical , the researchers describe a novel optical ... low as 6.3 ppm (parts per million). It requires ... "Traditionally explosives detection has involved looking for metals that ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2Detecting trace amounts of explosives with light 2
... on raising capital from investors. This installment focuses on the term ... equity capital, the offering terms are summarized in what is referred ... angel investors , it is typical for the company to ... want to negotiate the initial term sheet, especially if one of ...
... everyone will be famous for 15 minutes, couldn't imagine the influence ... his prediction. , ,With these tools, everyone can have their 15 ... seems that 15 minutes is about all anyone has time for ... , ,I was reminded of this after coming back from ...
... Harari Milwaukee, Wis . - Oren Harari ... - to convey the importance of innovation. , ,Not just to ... Manufacturing Matters conference , but to business organizations in a number ... Break From the Pack: How to Compete in a Copycat Economy ...
Cached Biology Technology:Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 2Visions: Innovating like Madonna and Willie Nelson (and Steve Jobs) 3
(Date:7/10/2014)... , June 27, 2014  Pomerantz LLP has ... Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) and certain ... United States District Court, Middle District of ... behalf of a class consisting of all persons ... securities between December 17, 2013 and May 22, ...
(Date:7/10/2014)... -- It is a great honor for Avery Biomedical ... world-renowned Thoracic and Cardiovascular surgeon, Mark E Ginsburg, M.D., ... with over 34 years of experience, is currently practicing ... Regional Medical Center. Dr. Ginsburg has been implanting the ... considered an expert in the implantation of the Avery ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch ... A Chinese Top 5 smartphone OEM has selected FPC1021 for ... in October 2014.   FPC is proud to ... which has a planned date for the start of mass ... this phone of 3 million units. The Chinese OEM wants ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2
... MDAs you decide what to get dad for Father,s Day, you ... conceived. If he smoked, your genes are likely damaged, and your ... increased. A new research report appearing online in the ... humans that men who smoke before conception can damage the genetic ...
... asks children who have each been assigned a wetland plant ... other "organisms" their assigned plant or animal interacts with in ... the teacher describes an event that affects one "organism." That ... tug then tug on their strings in turn. The ...
... leaf is different from the back of a leaf and the ... tomato or an Arabidopsis plant superficially appears to be ... Don,t let its appearance fool you; there is an underlying asymmetry ... a while for scientists to discover it. The story begins with ...
Cached Biology News:Happy Father's Day! Another reason why dads and hopeful dads should quit smoking now 2Foundational concept of ecology tested by experiment 2Foundational concept of ecology tested by experiment 3Foundational concept of ecology tested by experiment 4Is your leaf left-handed? 2Is your leaf left-handed? 3
... The system consists ... (Cat. No. 17001-082) and ... 17002-080). It is complete ... promoting agents, and requires ...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Rabbit polyclonal to Parathyroid Hormone ... all tested applications). ... to extracellular amino acids 99-116 of ... Entrez Gene ID: ...
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
Biology Products: